Menu
Live News EQUITY H impact

REGN: FDA, EMA Accept Cemdisiran Apps

Regeneron Pharmaceuticals announces FDA and EMA acceptance of regulatory applications for cemdisiran to treat generalized myasthenia gravis

REGN

Regeneron Pharmaceuticals Announces That Both The FDA And EMA Have Accepted Regulatory Applications For Cemdisiran To Treat Adult Patients With Generalized Myasthenia Gravis Who Are Anti-Acetylcholine Receptor Antibody-Positive